Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• GlimeliusBEkstromKHoffmanKRandomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnn Oncol199782163168
   PubMed Web of Science ®Google Scholar
• WagnerADGrotheWHaertingJKleberGGrotheyAFleigWEChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol200624182903290916782930
   PubMed Web of Science ®Google Scholar
• CasarettoLSousaPLMariJJChemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysisBraz J Med Biol Res200639443144016612465
   PubMed Web of Science ®Google Scholar
• WagnerADUnverzagtSGrotheWChemotherapy for advanced gastric cancerCochrane Database Syst Rev20103CD004064
   PubMed Web of Science ®Google Scholar
• IwaseHShimadaMTsuzukiTA phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancerOncology2011801–2768321659786
   PubMed Web of Science ®Google Scholar
• KoizumiWNakayamaNTanabeSA multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)Cancer Chemother Pharmacol201269240741321796483
   PubMed Web of Science ®Google Scholar
• KimJYDoYRParkKUMulticenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancerCancer Chemother Pharmacol201167352753220461377
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSV325 Study GroupPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• AjaniJAMoiseyenkoVMTjulandinSV-325 Study GroupClinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study GroupJ Clin Oncol200725223205320917664467
   PubMed Web of Science ®Google Scholar
• AjaniJAMoiseyenkoVMTjulandinSV-325 Study GroupQuality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study GroupJ Clin Oncol200725223210321617664468
   PubMed Web of Science ®Google Scholar
• HwangIGJiJHKangJHA multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancerJ Geriatr Oncol20178317017528119041
   PubMed Web of Science ®Google Scholar
• Al-BatranSEHartmannJTProbstSArbeitsgemeinschaft Internistische OnkologiePhase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieJ Clin Oncol20082691435144218349393
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSUpper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United KingdomCapecitabine and oxaliplatin for advanced esophagastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• Al-BatranSEHartmannJTHofheinzRBiweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or resophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol200819111882188718669868
   PubMed Web of Science ®Google Scholar
• LouvetCAndreTTigaudJMPhase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsJ Clin Oncol200220234543454812454110
   PubMed Web of Science ®Google Scholar
• Al-BatranSEAtmacaAHegewisch-BeckerSPhase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancerJ Clin Oncol200422465866314966088
   PubMed Web of Science ®Google Scholar
• ZhangJChenRXZhangJEfficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancerChin Med J (Engl)2012125122144215022884144
   PubMed Web of Science ®Google Scholar
• YehYSTsaiHLMaCJA retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patientsChemotherapy201258541141823306825
   PubMed Web of Science ®Google Scholar
• CatalanoVBisonniRGrazianoFA phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseasesGastric Cancer201316341141923065042
   PubMed Web of Science ®Google Scholar
• ChenSSYangXCChiFA phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinomaOncol Res201320732733223879173
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• CirilloMVenturiniMCiccarelliLCoatiFBortolamiOVerlatoGClinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaireAnn Oncol200920121929193519622510
   PubMed Web of Science ®Google Scholar
• PowerDGKelsenDPShahMAAdvanced gastric cancer slow but steady progressCancer Treat Rev201036538439220176443
   PubMed Web of Science ®Google Scholar
• LuoHYXuRHZhangLA pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancerChemotherapy200854322823518560231
   PubMed Web of Science ®Google Scholar
• LeeHHHurHKimSHParkARKimWJeonHMOutcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysisCancer Res Treat2010421182320369047
   PubMed Web of Science ®Google Scholar
• HacibekirogluIKodazHErdoganBComparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancerMol Clin Oncol2015351160116426623070
   PubMedGoogle Scholar
• LordickFLorenzenSYamadaYIlsonDOptimal chemotherapy for advanced gastric cancer: is there a global consensus?Gastric Cancer201417221322524048758
   PubMed Web of Science ®Google Scholar
• NishiyamaMWadaSDocetaxel: its role in current and future treatments for advanced gastric cancerGastric Cancer200912313214119890692
   PubMed Web of Science ®Google Scholar
• Al-BatranSEPauligkCHomannNThe feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)Eur J Cancer201349483584223063354
   PubMed Web of Science ®Google Scholar
• Van CutsemEBoniCTaberneroJDocetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyAnn Oncol201526114915625416687
   PubMed Web of Science ®Google Scholar